In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States.

We evaluated the susceptibility of 8,123 Gram-positive bacteria from patients with skin and skin structure infections at 33 US hospitals. Ceftobiprole inhibited 99.8% of Staphylococcus aureus, including 99.5% of methicillin-resistant isolates, at ≤2 mg/L. Ceftobiprole was highly active against β-hemolytic streptococci, coagulase-negative staphylococci, viridans group streptococci, and Enterococcus faecalis isolates.